A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?

Lung Cancer. 2020 Jul:145:213-215. doi: 10.1016/j.lungcan.2020.04.029. Epub 2020 May 4.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / pathology
  • Coronavirus Infections / virology
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neutropenia / complications
  • Neutropenia / drug therapy*
  • Neutropenia / pathology
  • Neutropenia / virology
  • Neutrophils / drug effects
  • Neutrophils / pathology
  • Neutrophils / virology
  • Nivolumab / therapeutic use
  • Oxygen / therapeutic use
  • Pandemics
  • Pneumonia / complications
  • Pneumonia / drug therapy*
  • Pneumonia / pathology
  • Pneumonia / virology
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / pathology
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Small Cell Lung Carcinoma / complications
  • Small Cell Lung Carcinoma / drug therapy*
  • Small Cell Lung Carcinoma / pathology
  • Small Cell Lung Carcinoma / virology

Substances

  • Nivolumab
  • Oxygen